Rematazolam Besylate
2022-EA-2
Approved small_molecule active
Quick answer
Rematazolam Besylate for Emergence Agitation is a Approved program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Emergence Agitation
- Phase
- Approved
- Modality
- small_molecule
- Status
- active